Global pneumonia market is expected to witness lucrative growth as the consequence of rising number of geriatric population and increasing prevalence of lung diseases, viral infections & heart diseases, among children thereby elevating the risk of developing pneumonia. Treatment advances facilitates benefits such as better efficacy & potency and lower incidence of potential side effects which are expected to drive the demand for the market over the forecast period. These advances include advent of new drugs namely trimethoprim-sulfamethoxazole and parental pentamidine isethionate. Moreover, better drug delivery & targeting techniques such as nebulization and aerosolization of drug facilitating relative ease of administration, high attainable drug levels and low side-effects are expected to drive the market growth potential further over the forecast period.
Access full research report at:
The global pneumonia market is segmented on the basis of treatment drugs & vaccines market and mode of acquisition. On the basis of treatment drugs and vaccines, it is further segmented into antibiotics such as cephalosporins, penicillin, fluoroquinolones, tetracyclines, amoxicillin & vancomycin wheras vaccines include PCV13 & PPV23. On the basis of mode of acquisition, it is classified into hospital acquired pneumonia, community acquired pneumonia and ventilator acquired pneumonia. As of 2014, treatment drugs segment held the largest share of pneumonia market owing to the benefits such as better drug response, fast onset of action and higher efficacy & potency. On the basis of mode of acquisition, hospital acquired pneumonia held the largest market owing to factor such as increasing multidrug resistance in microorganisms in the hospital settings.
Geographically, pneumonia market is segmented into North America, Europe, Asia Pacific, Latin America and MEA. As of 2014, North America held the largest share in the pneumonia market owing to factors such as increasing multi drug resistance by microorganisms in viral infections among children and adults. Rising geriatric population and government initiatives are also responsible to drive the demand for pneumonia market in this region. For Instance, WHO and UNICEF Integrated Global Action Plan For Pneumonia and Diarrhoea (GAPPD) aims to accelerate pneumonia control with a combination of interventions to protect, prevent, and treat pneumonia in children and availability of advanced healthcare systems. Additionally, high awareness and disposable income are potential contributors to the growth of this market over the forecast period. Asia Pacific region is anticipated to be the fastest growing market due to prominent growth factors such as rising accessibility, increasing patient awareness, improving healthcare infrastructure and incremental disposable income.
The major players of the pneumonia market include Sanofi, AstraZeneca, GlaxoSmithCline, Eli Lilly, Merck & Co., Pfizer, Novartis and Baxter International Inc. These companies focus on crucial strategies such as development of innovative diagnostic systems, targeting developing regions and providing services aimed at better patient information & quality of life with better view for market penetration.
Request for TOC of this report:
No comments:
Post a Comment